Moomoo AI 已提取核心訊息
On December 31, 2023, a Schedule 13G/A filing was made with the United States Securities and Exchange Commission by PFM Health Sciences, LP, PFM Health Sciences GP, LLC, Partner Asset Management, LLC, and Brian D. Grossman, collectively referred to as the Reporting Persons, regarding their ownership in bluebird bio, Inc. The filing indicates that these entities and individuals collectively hold 2,042,651 shares of bluebird bio's common stock, which represents approximately 1.9% of the company's outstanding common stock as of November 3, 2023. The Reporting Persons have shared voting and dispositive power over these shares. The filing was certified as true and correct by Darren Mooney, authorized signatory, on February 14, 2024. The address for the principal business office of the Reporting Persons is in San Francisco, California. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of bluebird bio, Inc.
On December 31, 2023, a Schedule 13G/A filing was made with the United States Securities and Exchange Commission by PFM Health Sciences, LP, PFM Health Sciences GP, LLC, Partner Asset Management, LLC, and Brian D. Grossman, collectively referred to as the Reporting Persons, regarding their ownership in bluebird bio, Inc. The filing indicates that these entities and individuals collectively hold 2,042,651 shares of bluebird bio's common stock, which represents approximately 1.9% of the company's outstanding common stock as of November 3, 2023. The Reporting Persons have shared voting and dispositive power over these shares. The filing was certified as true and correct by Darren Mooney, authorized signatory, on February 14, 2024. The address for the principal business office of the Reporting Persons is in San Francisco, California. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of bluebird bio, Inc.
2023年12月31日，PFM Health Sciences, LP、PFM Health Sciences GP, LLC、Partner Asset Management, LLC和Brian D. Grossman（統稱爲 “申報人”）向美國證券交易委員會提交了附表13G/A的文件。該文件顯示，這些實體和個人共持有藍鳥生物普通股的2,042,651股，這意味着截至2023年11月3日，該公司已發行普通股的約1.9％。申報人對這些股票擁有共同的投票權和處置權。該文件於2024年2月14日由授權簽署人達倫·穆尼認證爲真實和正確。申報人主要業務辦公室的地址在加利福尼亞州的舊金山。該文件稱，收購這些股票不是爲了改變或影響藍鳥生物公司的控制權。
2023年12月31日，PFM Health Sciences, LP、PFM Health Sciences GP, LLC、Partner Asset Management, LLC和Brian D. Grossman（統稱爲 “申報人”）向美國證券交易委員會提交了附表13G/A的文件。該文件顯示，這些實體和個人共持有藍鳥生物普通股的2,042,651股，這意味着截至2023年11月3日，該公司已發行普通股的約1.9％。申報人對這些股票擁有共同的投票權和處置權。該文件於2024年2月14日由授權簽署人達倫·穆尼認證爲真實和正確。申報人主要業務辦公室的地址在加利福尼亞州的舊金山。該文件稱，收購這些股票不是爲了改變或影響藍鳥生物公司的控制權。
有用
沒用